These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29265387)

  • 1. Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.
    Morimoto M; Shimakawa S; Hashimoto T; Kitaoka T; Kyotani S
    J Clin Pharm Ther; 2018 Aug; 43(4):571-573. PubMed ID: 29265387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.
    Jogamoto T; Yamamoto Y; Fukuda M; Suzuki Y; Imai K; Takahashi Y; Inoue Y; Ohtsuka Y
    Epilepsy Res; 2017 Feb; 130():7-12. PubMed ID: 28081475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with dravet syndrome in the era of stiripentol: A French cohort cross-sectional study.
    De Liso P; Chemaly N; Laschet J; Barnerias C; Hully M; Leunen D; Desguerre I; Chiron C; Dulac O; Nabbout R
    Epilepsy Res; 2016 Sep; 125():42-6. PubMed ID: 27389706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
    Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
    Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
    Inoue Y; Ohtsuka Y;
    Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stiripentol (Diacomit) for Dravet syndrome.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):e48-e50. PubMed ID: 33976090
    [No Abstract]   [Full Text] [Related]  

  • 8. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
    Trivisano M; Specchio N; Vigevano F
    Eur J Paediatr Neurol; 2015 Mar; 19(2):248-50. PubMed ID: 25510386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stiripentol: new preparation. Severe myoclonic epilepsy of infancy: promising.
    Prescrire Int; 2005 Apr; 14(76):57-9. PubMed ID: 15875342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.
    Jullien V; Chhun S; Rey E; Dulac O; Tod M; Chiron C; Pons G
    Clin Pharmacokinet; 2015 May; 54(5):527-36. PubMed ID: 25503589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stiripentol: A Review in Dravet Syndrome.
    Frampton JE
    Drugs; 2019 Nov; 79(16):1785-1796. PubMed ID: 31617141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome.
    Kouga T; Shimbo H; Iai M; Yamashita S; Ishii A; Ihara Y; Hirose S; Yamakawa K; Osaka H
    Brain Dev; 2015 Feb; 37(2):243-9. PubMed ID: 24819914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both?
    Latour P; Biraben A; Polard E; Bentué-Ferrer D; Beauplet A; Tribut O; Allain H
    Hum Psychopharmacol; 2004 Apr; 19(3):193-203. PubMed ID: 15079854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
    Chiron C; Marchand MC; Tran A; Rey E; d'Athis P; Vincent J; Dulac O; Pons G
    Lancet; 2000 Nov; 356(9242):1638-42. PubMed ID: 11089822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?
    Chiron C; Helias M; Kaminska A; Laroche C; de Toffol B; Dulac O; Nabbout R; An I
    Epilepsia; 2018 Sep; 59(9):1705-1717. PubMed ID: 30132836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapeutic procedures in Dravet syndrome.
    Chiron C
    Dev Med Child Neurol; 2011 Apr; 53 Suppl 2():16-8. PubMed ID: 21504427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.
    Elliott J; McCoy B; Clifford T; Wells GA; Coyle D
    Pharmacoeconomics; 2018 Oct; 36(10):1253-1261. PubMed ID: 29761351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome.
    Aras LM; Isla J; Mingorance-Le Meur A
    Epilepsy Behav; 2015 Mar; 44():104-9. PubMed ID: 25666511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stiripentol: efficacy and tolerability in children with epilepsy.
    Perez J; Chiron C; Musial C; Rey E; Blehaut H; d'Athis P; Vincent J; Dulac O
    Epilepsia; 1999 Nov; 40(11):1618-26. PubMed ID: 10565591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.